Health Status After Switching Angiotensin-converting Enzyme Inhibitors or Angiotensin Receptor Blockers to Sacubitril-valsartan in Patients with Heart Failure with Reduced Ejection Fraction from Rural Tanzania: an Interventional Study

Angiotensin-neprilysin inhibitors (ARNI) are beneficial in patients with heart failure with reduced ejection fraction. No study evaluating ARNI has been conducted in sub-Saharan Africa (except South Africa) yet, where heart failure is a major health problem. Before implementing ARNI in Tanzania, a study evaluating the benefit and safety of ARNI in Africans is needed. The aim of this interventional pre-post study is to evaluate the health status of symptomatic patients with heart failure with reduced ejection fraction who are under a chronic heart failure therapy, before and after switching angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) to ARNI. Participants will be recruited at the Heart and Lung Clinic of the St Francis Regional Referral Hospital in Ifakara in rural Tanzania during a study period of 30 months, including 10 months of follow-up. A total of 238 participants will be included. The investigators hypothesize that health status, expressed by the Kansas City Cardiomyopathy Questionnaire summary score and 6-minute walking test, will improve after switching from ACE-inhibitors or ARB to ARNI. In Tanzania, sacubitril/valsartan is registered under the name Uperio®.

Start Date01 Mar 2025

Sponsor / Collaborator

Swiss Tropical & Public Health Institute

[+1]

NCT06693674

/ RecruitingPhase 3IIT

Role of Sacubitril-Valsartan for Right Ventricular Reverse Remodeling in Adults with Tetralogy of Fallot and Ebstein's Anomaly: a Randomized Controlled Pilot Clinical Trial

The purpose of this study is to compare changes in RV structure and function, biomarkers, and patient reported outcomes between TOF patients randomized to an ARNI vs placebo.

Start Date01 Feb 2025

Sponsor / Collaborator

Mayo Clinic

[+1]

NCT06712030

/ Not yet recruitingPhase 3IIT

Effect of Pharmacological Treatment with Angiotensin Receptor/Neprilysin Inhibitors on Transthyretin Cardiac Amyloidosis and Heart Failure with Reduced Ejection Fraction (SAVA-TTR)

Prospective, randomized, multicenter, open-label clinical trial to evaluate the safety and efficacy of Sacubitril/Valsartan (Sac/Vals) compared to no initiation of the drug in patients with transthyretin cardiac amyloidosis (ATTR) and heart failure with reduced ejection fraction (LVEF ≤40%). The primary objective is to determine the impact of Sac/Vals treatment on systolic function by assessing the change in LVEF on echocardiogram at 12-month follow-up.

Start Date01 Jan 2025

Sponsor / Collaborator

Hospital Majadahonda SA

100 Clinical Results associated with Sacubitril/Valsartan

100 Translational Medicine associated with Sacubitril/Valsartan

100 Patents (Medical) associated with Sacubitril/Valsartan

521

Literatures (Medical) associated with Sacubitril/Valsartan

01 Mar 2025·BRAIN RESEARCH

Lactobacillus casei Zhang prevents hippocampal atrophy and cognitive impairment in rats with type 2 diabetes by regulating blood glucose levels

Article

Author: Liu, Sijie ; Lin, Fuchun ; Kang, Yan ; Cheng, Linlin ; Chen, Xi ; Wang, Xuxia ; Cai, Yue

PURPOSE:

Lactobacillus casei Zhang (LCZ) has health benefits, such as the ability to improve blood glucose levels in individuals with type 2 diabetes mellitus (T2DM). However, little is known about the effects of LCZ on brain structural plasticity and cognitive function in T2DM. The aims of this study were to determine whether LCZ can prevent and alleviate brain damage and memory impairment in T2DM, and to understand the mechanisms underlying the effects of LCZ in T2DM.

METHODS:

Forty-one male Sprague-Dawley rats were divided into the saline control (CON, n = 14), T2DM (n = 14) and T2DM + LCZ (n = 13) groups. Magnetic resonance imaging (MRI) was used to evaluate alterations in brain structure among these three groups. The novel object recognition and Y-maze tests were conductedto assess cognitive function. Histological and immunohistochemical analysis, including Nissl staining, Golgi-Cox staining and glial fibrillary acidic protein immunostaining, were performed to explore the pathophysiological mechanisms underlying brain structural changes.

RESULTS:

T2DM rats presented hyperglycemia, cognitive decline, hippocampal atrophy, and damage to hippocampal neurons and astrocytes. Compared with those in the T2DM groups, rats in the T2DM + LCZ group presented lower blood glucose levels, better cognitive function, a larger hippocampal volume, and more normal hippocampal neurons and astrocytes. There was no significant difference in these metrics between rats in the T2DM + LCZ and CON groups.

CONCLUSION:

Hyperglycemia-induced damage to hippocampal neurons and astrocytes may lead to hippocampal atrophy and cognitive dysfunction in T2DM. LCZ can effectively prevent this damage by regulating blood glucose levels, preventing brain atrophy and cognitive impairment in T2DM rats. These findings provide a scientific basis for the clinical application of LCZ.

01 Jan 2025·JOURNAL OF ETHNOPHARMACOLOGY

Qianyang Yuyin granules alleviate hypertension-induced vascular remodeling by inhibiting the phenotypic switch of vascular smooth muscle cells

Article

Author: Zheng, Yawei ; Fan, Yadong ; Liu, Ming ; Zhang, Siqi ; Zhang, Haitao ; Sun, Zeqi ; Zheng, Ziwen ; Yan, Xiwu ; Fang, Zhuyuan ; Jialiken, Dinala ; Zhang, Weiting

ETHNOPHARMACOLOGICAL RELEVANCE:

Qianyang Yuyin granules (QYYY) have been used clinically to treat hypertension for over two decades. Previous clinical trials have shown that QYYY can improve vascular elastic function in hypertensive patients. However, the underlying pharmacological mechanism is unclear.

AIM OF THE STUDY:

To elucidate the effects and mechanisms of QYYY on vascular remodeling using a multidisciplinary approach that includes network pharmacology, proteomics, and both in vitro and in vivo experiments.

MATERIALS AND METHODS:

The main components of QYYY were identified using ultra-high-performance liquid chromatography and high-resolution mass spectrometry. Network pharmacology and molecular docking were employed to predict QYYY's primary active ingredients, potential therapeutic targets and intervention pathways in hypertensive vascular remodeling. We induced hypertension in male C57BL/6 mice by infusing angiotensin II (Ang II) via osmotic minipumps, and performed pre-treatment with QYYY or Sacubitril/valsartan (Entresto). Blood pressure was monitored in vivo, followed by the extraction of aortas to examine pathological structural changes and alterations in protein expression patterns. The expression and location of proteins involved in the HIF-1α/TWIST1/P-p65 signaling pathway were investigated, as well as markers of vascular smooth muscle cells (VSMCs) phenotypic switch. In vitro, we studied the effects of QYYY water extract on Ang II-stimulated human aortic VSMCs. We investigated whether QYYY could affect the HIF-1α/TWIST1/P-p65 signaling pathway, thereby ameliorating apoptosis, autophagy, and phenotype switch in VSMCs.

RESULTS:

We identified 62 main compounds in QYYY, combined with network pharmacology, speculated 827 potentially active substances, and explored 1021 therapeutic targets. The KEGG pathway analysis revealed that the mechanisms of action associated with QYYY therapy potentially encompass various biological processes, including metabolic pathways, TNF signaling pathways, apoptosis, Ras signaling pathways, HIF-1 signaling pathways, autophagy-animal pathways. In hypertensive mice, QYYY restored abnormally elevated blood pressure, vascular remodeling, and inflammation with a dose-response relationship while altering abnormal protein patterns. In vitro, QYYY could inhibit abnormal proliferation, migration, intracellular Ca²⁺ accumulation and cytoskeletal changes of VSMCs. It improved mitochondrial function, reduced ROS levels, stabilized membrane potential, prevented cell death, and reduced overproduction of TGF-β1, TNF-a, and IL-1β.

CONCLUSION:

QYYY may be able to inhibit the overactivation of the HIF-1α/TWIST1/P-p65 signaling pathway, improve the phenotypic switch, and balance apoptosis and autophagy in VSMCs, thereby effectively improving vascular remodeling caused by hypertension.

01 Jan 2025·Acta Crystallographica Section E-Crystallographic Communications

Crystal structure of luliconazole

Article

Author: Chęcińska, Lilianna ; Ben, Anna

The crystal structure of luliconazole {LCZ; C14H9Cl2N3S2; systematic name: (E)-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene](1H-imidazol-1-yl)acetonitrile} is reported. In the molecule of the title compound, the dithiolane ring adopts an envelope conformation, while the dichlorophenyl ring exhibits disorder. In the crystal packing of luliconazole, only two intermolecular C–H...N hydrogen bonds are observed. Hirshfeld surface analysis reveals that the most dominant contacts are H...N/N...H, H...Cl/Cl...H, H...H and C...H/H...C.

151

News (Medical) associated with Sacubitril/Valsartan

11 Feb 2025

·medcitynews.com

Novartis’s $925M Anthos Acquisition Brings Back Cardio Drug That Stops Blood Clots - MedCity News

Novartis is expanding its prospects in cardiometabolic disease by striking a deal to acquire Anthos Therapeutics, a company in pivotal testing with a blood clot-preventing drug that could offer advantages over anticoagulants currently sold by some of its big pharmaceutical peers. According to deal terms announced Tuesday, Novartis is paying $925 million up front for Anthos. Achieving milestones could bring the payout to as much as $3.1 billion. The deal, which still needs regulatory approvals, is expected to close in the first half of this year. The acquisition represents a homecoming for Anthos’s main asset, abelacimab, a drug that originated in Novartis’s labs. Anthos launched in 2019 with $250 million from Blackstone Life Sciences and a license for global rights to the Novartis drug, known then as MAA868. At the time of the deal, this drug was in mid-stage clinical development. Novartis retained a minority stake in Cambridge, Massachusetts-based Anthos. Sponsored Post The Funding Model for Cancer Innovation is Broken — We Can Fix It Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches. By Eve McDavid - CEO of Mission-Driven Tech Abelacimab is a monoclonal antibody designed to bind to a clotting protein called Factor XI. Doing so is intended to block activation of this protein that plays a key role in blood coagulation. Drugs are already available to reduce the risk of stroke and blood clots. Xarelto, from Bayer and Johnson & Johnson, and Eliquis, marketed by Bristol Myers Squibb and Pfizer, are blockbuster sellers. But both blood-thinning medicines also come with bleeding risks. Anthos already has clinical trial results topping Xarelto. A Phase 2 test of abelacimab was stopped early in 2023 due to “overwhelming reduction in bleeding.” Detailed trial results published last month in the New England Journal of Medicine show a 62% reduction in major bleeding or clinically relevant non-major bleeding and a 67% reduction in major bleeding compared to treatment with Xarelto. Anthos also reported its drug achieved an 89% reduction in gastrointestinal bleeding. Abelacimab, which is administered intravenously at first and then by monthly subcutaneous injection thereafter, is currently in Phase 3 testing in patients with atrial fibrillation who have a high risk for stroke or systemic embolism. Two additional Phase 3 studies are underway testing the drug as a way to prevent the recurrence of blood clots in patients with cancer. Anthos expects these studies will post data in the second half of 2026. “Abelacimab has the potential to be an important treatment option for the millions of patients globally with atrial fibrillation at high risk of stroke, and we could not have more conviction in the potential of this asset,” Anthos CEO Bill Meury said in a prepared statement. “With its deep roots in the cardiovascular space, Novartis is especially well positioned to advance abelacimab’s clinical development and bring this innovative product to healthcare providers and patients.” presented by Health IT Transforming Patient Care: The Role of AI-Powered Assistants The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes. By IT Medical Cardiometabolic disease is one of four therapeutic areas that Novartis has identified as core to its strategy. The others are immunology, neuroscience, and oncology. The Anthos acquisition is timely for Novartis. The Swiss pharma giant’s cardiometabolic product lineup is currently anchored by Entresto, a heart failure drug that accounted for $7.8 billion in worldwide sales in 2024, a 30% increase compared to the prior year. But Entresto faces pricing challenges. Patents protecting the product expire in 2025 and 2026. Entresto was also selected as one of the first 10 drugs subject to price negotiation by the Centers for Medicare and Medicaid Services. The negotiated price will take effect in 2026. There have been other efforts to beat Xarelto and Eliquis. In 2023, Bayer stopped a Phase 3 test of asundexian in atrial fibrillation after the study’s data monitoring committee concluded the Factor XIa-blocking oral small molecule was unlikely to be more effective than Eliquis. Meanwhile, Bristol Myers Squibb’s oral Factor XIa inhibitor milvexian is currently in Phase 3 testing in acute coronary syndrome, atrial fibrillation, and secondary stroke prevention. Image: Magicmine, Getty Images

AcquisitionPhase 3Clinical ResultPhase 2Drug Approval

31 Jan 2025

·endpts.com

Novartis claims best earnings in years, validating shift to pure-play strategy

Novartis said Friday that last year was one of its “strongest” financial performances in its history following a multiyear reorg as a pure-play pharma company, bolstered by steady growth of its top three medicines and a skyrocketing cholesterol franchise. CEO Vas Narasimhan said on a media call that the company exceeded its full-year guidance for both sales and operating income. The Swiss drugmaker’s 2024 sales grew 12% to $45.4 billion, according to an earnings release . The update was not a complete surprise, because the company upped its sales guidance through 2028 in November. Novartis’ cholesterol drug Leqvio saw the most growth in 2024, with sales soaring 112% to $754 million. But its top three best sellers were heart failure medicine Entresto ($7.8 billion), psoriasis treatment Cosentyx ($6.1 billion) and multiple sclerosis drug Kesimpta ($3.2 billion). In 2023, the company completed a long-term restructuring process that saw it integrate its pharmaceuticals and oncology business units into a so-called innovative medicines unit, and zero in on four core therapeutic areas: cardiovascular, renal and metabolic (CRM), as well as oncology, immunology and neuroscience. “When you look at [this change] from a value creation standpoint, in January 2018 the market capitalization of Novartis was $196 billion, and you can see today that [it] stands at over $200 billion,” Narasimhan said on the second media call. “The strategy of focusing the company has unlocked value and actually enabled Novartis to be much stronger for the long run.” Last year, the drugmaker slashed the size of its development and commercial functions with an eye to a leaner structure that would allow it to focus on “the biggest opportunities” in its pipeline. It’s targeting 15 new launches or label expansions over the next few years, starting with a potential indication for its immunoglobulin A nephropathy drug Fabhalta. The factor B inhibitor was due for an FDA adcomm meeting next month to discuss its risk-benefit profile in C3 glomerulopathy, but the agency called the meeting off earlier this week. “Our understanding is that the FDA no longer deemed it necessary to hold an advisory committee meeting,” Narasimhan told reporters. “We think it’s based on the overall data package we’ve been able to generate and the additional follow-on data that we’ve provided.” Narasimhan also stressed that Novartis remains a leader in the radiopharmaceutical space, with close to $2 billion in yearly sales from radioligand products, a global manufacturing footprint and more than 15 assets in the clinic using lutetium or actinium isotopes. The company made several investments in the approach last year, including a $1 billion bet on Mariana Oncology. Novartis plans to carry on with this kind of dealmaking , Narasimhan said. “But I think it’s really important to note that right now, lutetium is the isotope that has the most data and is the only approved isotope,” he continued, adding that newer isotopes such as actinium and lead have yet to demonstrate the necessary risk-benefit profile for approval and broad use. Also on the call, the company’s chief medical officer Shreeram Aradhye said it had discontinued development of a Phase 2 candidate for Sjögren’s syndrome. Novartis dropped work on anti-CD40 antibody iscalimab because its risk-benefit profile to date was not competitive, Aradhye said. But the company is still advancing another antibody program for Sjögren’s called ianalumab. In 2022, the drugmaker gave up on advancing iscalimab for liver transplant patients for similar reasons. Editor’s note: This story has been updated to add more comments from the company’s calls.

Phase 2

31 Jan 2025

·www.biopharmadive.com

Novartis sets ‘ambitious’ target; Skyrizi, Rinvoq sales climb

Today, a brief rundown of news involving Novartis and AbbVie, as well as updates from Biogen, Merck & Co. and Sanofi that you may have missed.Novartis on Friday reported fourth quarter and full year results that beat analyst forecasts, driven by sales growth for a range of products including the heart drug Entresto, cholesterol-lowering medicine Leqvio and breast cancer therapy Kisqali. Net sales rose from about $45.4 billion to $50.3 billion between 2023 and 2024, with net income also climbing from $8.6 billion to just over $11.9 billion. Novartis said net sales should grow by mid- to high-single digits in 2025, an ambitious projection given the coming patent expiration for Entresto this year, wrote Stifel analyst Eric Le Berrigaud. The numbers are the result of a wise strategy of focus on key brands and key markets that is paying off, he wrote. Ben FidlerSales of AbbVies autoimmune drugs Skyrizi and Rinvoq are making up for the declines in Humira revenue due to biosimilar competition. Alongside fourth quarter earnings Friday, AbbVie said it now expects annual Skyrizi and Rinvoq sales to reach $31 billion by 2027, $4 billion more than it forecast a year ago. By that time, Skyrizi will account for $20 billion annually roughly what Humira earned at its peak and Rinvoq $11 billion, AbbVie said. Those estimates surpassed consensus estimates of $29 billion in combined sales by 2027, William Blair analyst Matt Phipps wrote in a note to clients. AbbVies revenue in 2024 climbed to $56 billion, a 4% increase over 2023 and ahead of Wall Streets expectations. Shares rose about 7% in Friday morning trading. Jonathan GardnerDaiichi Sankyo CEO Sunao Manabe will be replaced by Chief Operating Officer Hiroyuki Okuzawa as head of the Japanese drugmaker on April 1, the company said Friday. Manabe has steered Daiichi since 2019, overseeing its rise as a leader in the development of antibody-drug conjugates. The company has struck a series of lucrative ADC-focused alliances with AstraZeneca and Merck & Co. under his watch, and seen the cancer drug Enhertu become a blockbuster medicine. Manabe will transition to executive chair once Okuzawa, who has been with the company since 1986, takes over. Ben FidlerThe European Commission wont yet approve Eisai and Biogens Alzheimers drug Leqembi, instead asking its drugs regulator to first review new safety information that became available after the committee endorsed the drug in November, Biogen said Friday. That regulator, the European Medicines Agency, had previously found Leqembis risks outweighed its benefits before changing course after the companies appealed. The EMA will now seek, at a February meeting, an updated opinion on potential safety considerations and monitoring measures. Though not ideal, the request should not necessarily lead to an opinion reversal given the strict risk management protocols currently in place, wrote RBC Capital Markets Brian Abrahams. Ben FidlerMerck stopped early another trial of its new lung-disease drug Winrevair because of evidence suggesting its clear benefits for people with pulmonary arterial hypertension. The trial, called Hyperion, tested Winrevair and background therapy against placebo and additional treatment in people with whats known as functional Class 2 or 3 PAH, when the disease limits activity because of shortness of breath. As Winrevair already proved it worked in a study of more severely ill people with PAH, trial monitors decided it would be unethical for the placebo group in the Hyperion study not to receive treatment. Trial data will be released later this year and discussed at a future medical meeting. Launched last March, Winrevair recorded sales of $219 million through Sept. 30. Jonathan GardnerSanofi on Thursday said its antibody shot for respiratory syncytial virus, Beyfortus, became a blockbuster medicine in its first full year on the market. Sanofis 2024 earnings report showed the drug generated sales of 1.7 billion euros, or about $1.8 billion, and 841 million euros in the fourth quarter alone. Sanofi attributed the recent uptick mostly to sales in Europe. More broadly, though, Beyfortus launch accelerated once the company ramped up manufacturing to address supply constraints. Delilah Alvarado '

Drug ApprovalExecutive ChangeClinical ResultFinancial Statement

100 Deals associated with Sacubitril/Valsartan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C09DX04	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	CN	Novartis Pharma Schweiz AG	24 May 2021
Hypertension	JP	Novartis Pharma KK	29 Jun 2020
Left ventricular systolic dysfunction	US	Novartis Pharmaceuticals Corp.	01 Oct 2019
Reduced ejection fraction co-occurrent and due to chronic heart failure	EU	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	IS	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	LI	Novartis Europharm Ltd.	19 Nov 2015
Reduced ejection fraction co-occurrent and due to chronic heart failure	NO	Novartis Europharm Ltd.	19 Nov 2015
Heart Failure	CH	Novartis AG	17 Sep 2015
Chronic heart failure	US	Novartis Pharmaceuticals Corp.	07 Jul 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 3	KR	Chong Kun Dang Pharmaceutical Corp.	14 Oct 2024
Postmyocardial infarction syndrome	Phase 3	-	Novartis Pharmaceuticals Corp.	26 May 2021
Hydrops Fetalis	Phase 3	JP	Novartis Pharmaceuticals Corp.	07 May 2019
Acute myocardial infarction	Phase 3	US	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	CN	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	AR	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	AU	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	AT	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	BE	Novartis Pharmaceuticals Corp.	09 Dec 2016
Acute myocardial infarction	Phase 3	BR	Novartis Pharmaceuticals Corp.	09 Dec 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03168568 (VASCEND, Pubmed \| JACC Adv)	Phase 4	Heart Failure	79	Sacubitril/Valsartan	kzaquxyjhf(ufhbglbhjs) = gdafaifamz khujugasqf (aanoielqnx, 3.9) View more	Negative	01 Dec 2024
				Valsartan	kzaquxyjhf(ufhbglbhjs) = whudfyjiud khujugasqf (aanoielqnx, 2.8) View more
NCT01035255 (PARADIGM-HF, Pubmed \| Eur J Heart Fail)	Phase 3	Heart failure with reduced ejection fraction \| Chronic heart failure	8,399	Beta-blocker	xtmujiikcu(qqsliuonvt): HR = 0.47 (95% CI, 0.32 - 0.69) View more	Positive	19 Nov 2024
				No Beta-blocker
NCT02678312 (PANORAMA-HF, Pubmed \| Circulation) Manual	Phase 2/3	Heart Failure	375	Sacubitril/Valsartan	yjfnyosmbz(smidzkayup): OR = 0.91 (95% CI, 0.72 - 1.14), P-Value = 0.42 View more	Negative	25 Sep 2024
				Enalapril
NCT01920711 (PARAGON-HF, Pubmed \| Eur J Heart Fail)	Phase 3	Heart Failure	4,795	Sacubitril/valsartan	mefgqhwfvy(gnzgcnaxkn) = iqlzawtyay hnsuvphaaj (ulhbisioem, 0.0 - 0.2) View more	Positive	01 Sep 2024
				Valsartan	eojlwhtuez(jzhwqgxvas) = haxmoubxtf yeqnqgisbd (qebpbpqqye ) View more
ESC2024	Not Applicable	Heart Failure	-	Sacubitril/Valsartan (Patients aged below 80 years)	mptqodwehm(hlvvufisdg) = uxciwxdnop wglfcfjcvr (vwgufwogcb )	-	31 Aug 2024
				Sacubitril/Valsartan (Patients aged above 80 years)	mptqodwehm(hlvvufisdg) = hzmvtaycqy wglfcfjcvr (vwgufwogcb )
ESC2024	Not Applicable	Heart Diseases	-	ARNI Sacubitril/Valsartan	ramcuxdlqc(rluhbzgsrm) = upsruqeyzk cuntpwqiro (yveakyzwmp, 806 - 4330)	-	31 Aug 2024
ESC2024	Not Applicable	-	24	sacubitril/valsartan (Control)	kmgbnosztn(qhxrodhxwm) = gwaenrpmpk ueeclinwvn (flubcnifcc )	Negative	31 Aug 2024
				Sacubitril/Valsartan	kmgbnosztn(qhxrodhxwm) = aoejeqoaam ueeclinwvn (flubcnifcc )
ESC2024	Not Applicable	Heart Failure	-	sacubitril-valsartan (Patients <75 years old)	gmrdsbyqih(tlzxcmsahd) = very few patients were hospitalized for reasons related to angioedema, 16/44,743 in ≥75 y patients and 26/60,167 in those <75 y oixanfccpn (vcuynqtjlz )	-	30 Aug 2024
				sacubitril-valsartan (Patients ≥75 years old)
NCT02884206 (PERSPECTIVE, CTgov)	Phase 3	Chronic heart failure	592	Placebo of Valsartan+LCZ696 (LCZ696 200 mg Bid)	mfndembpaq(rlxmmaddvm) = deqpnlwvza lcwanjjyej (xmsbhdvawf, yoslohwupx - vldmvuetzk) View more	-	06 Aug 2024
				Placebo of LCZ696+Valsartan (Valsartan 160 mg Bid)	mfndembpaq(rlxmmaddvm) = pduycvsork lcwanjjyej (xmsbhdvawf, ipvgigxjhr - nxjztjlpqg) View more
NCT03988634 (PARAGLIDE-HF, CTgov)	Phase 3	Heart failure with normal ejection fraction	467	valsartan matching placebo+sacubitril/valsartan (Sacubitril/Valsartan (LCZ696))	feupexxdwm(scnnzwqfcp) = fvlfnwjphl aaqohpitbp (wanbaxwqgv, ejbzyttunc - agkipuxkpb) View more	-	29 Jul 2024
				sacubitril/valsartan matching placebo+valsartan (Valsartan)	feupexxdwm(scnnzwqfcp) = jzugefvbqj aaqohpitbp (wanbaxwqgv, nmuznntarc - gdnbkurahb) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis